Alan S Perelson Selected Research

Alan S Perelson Research Topics

Disease

106	Infections 03/2024 - 09/2002
24	Viremia 10/2023 - 09/2002
14	HIV Infections (HIV Infection) 01/2021 - 10/2002
14	Hepatitis C 08/2015 - 07/2002
12	Virus Diseases (Viral Diseases) 04/2024 - 03/2007
11	COVID-19 04/2024 - 01/2021
8	Persistent Infection 03/2024 - 03/2004
7	Disease Progression 01/2019 - 09/2004
6	Human Influenza (Influenza) 04/2014 - 08/2006
4	Chronic Hepatitis C 01/2017 - 02/2013
4	Fibrosis (Cirrhosis) 10/2016 - 11/2002
4	Chronic Hepatitis B 11/2010 - 01/2004
3	Acquired Immunodeficiency Syndrome (AIDS) 01/2021 - 04/2008
2	Inflammation (Inflammations) 01/2022 - 02/2011
2	Headache (Headaches) 10/2021 - 10/2016
2	Communicable Diseases (Infectious Diseases) 01/2021 - 01/2011
2	Fatigue 10/2016 - 11/2003
2	Liver Diseases (Liver Disease) 01/2015 - 11/2002
2	Coinfection 07/2014 - 04/2009
2	Hepatitis B 07/2014 - 01/2007
1	Pain (Aches) 10/2021
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 01/2021
1	Zika Virus Infection 10/2020
1	Respiratory Syncytial Virus Infections 11/2019
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 01/2018
1	Chronic Disease (Chronic Diseases) 07/2014
1	Body Weight (Weight, Body) 05/2014

Drug/Important Bio-Agent (IBA)

41	Antiviral Agents (Antivirals)IBA 01/2023 - 05/2003
25	RNA (Ribonucleic Acid)IBA 12/2021 - 09/2002
13	InterferonsIBA 01/2022 - 07/2002
10	VaccinesIBA 01/2018 - 09/2004
8	AntibodiesIBA 04/2023 - 12/2008
7	Monoclonal AntibodiesIBA 04/2024 - 01/2020
7	Viral RNAIBA 07/2022 - 05/2010
7	Ribavirin (Virazole)FDA LinkGeneric 01/2014 - 07/2002
6	AntigensIBA 12/2021 - 09/2004
6	Protease Inhibitors (Protease Inhibitor)IBA 01/2020 - 05/2008
5	bamlanivimabIBA 01/2023 - 09/2021
5	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 03/2007
5	Proteins (Proteins, Gene)FDA Link 01/2018 - 04/2005
5	CytokinesIBA 11/2017 - 03/2007
4	NucleosidesIBA 01/2018 - 02/2008
4	EpitopesIBA 01/2015 - 08/2010
3	Circular DNAIBA 03/2024 - 11/2017
3	Interferon Type IIBA 01/2022 - 04/2005
3	SofosbuvirIBA 01/2020 - 01/2014
3	Drug CombinationsIBA 01/2017 - 05/2010
3	NucleotidesIBA 10/2016 - 05/2009
3	Neutralizing AntibodiesIBA 01/2015 - 05/2008
3	Immunoglobulin G (IgG)IBA 11/2011 - 12/2008
3	Amino Acids FDA Link 01/2011 - 11/2002
3	Anti-Infective Agents (Microbicides)IBA 06/2009 - 07/2008
2	Biomarkers (Surrogate Marker)IBA 03/2024 - 06/2023
2	Broadly Neutralizing AntibodiesIBA 03/2024 - 09/2015
2	Nucleic AcidsIBA 12/2021 - 07/2014
2	Morphine (MS Contin)FDA LinkGeneric 01/2019 - 09/2016
2	daclatasvirIBA 10/2016 - 03/2013
2	2'- fluoro- 2'- methyl- 3',5'- diisobutyryldeoxycytidineIBA 01/2016 - 04/2012
2	SolutionsIBA 08/2014 - 05/2010
2	Oseltamivir (Tamiflu)FDA Link 04/2014 - 01/2011
2	Interferon-alpha (Interferon Alfa)IBA 02/2013 - 07/2007
2	AIDS VaccinesIBA 12/2012 - 10/2004
2	Reverse Transcriptase InhibitorsIBA 07/2011 - 04/2009
2	Amantadine (Aman)FDA LinkGeneric 01/2011 - 09/2008
2	Hepatitis B e AntigensIBA 11/2010 - 01/2007
2	Tenofovir (Viread)FDA Link 04/2009 - 04/2008
2	Emtricitabine (Emtriva)FDA Link 04/2008 - 01/2007
2	adefovir dipivoxil (Hepsera)FDA Link 01/2007 - 01/2004
1	mRNA VaccinesIBA 04/2023
1	Pathogen-Associated Molecular Pattern MoleculesIBA 01/2022
1	Interferon Regulatory FactorsIBA 01/2021
1	N,N'- (2,2'- (hexa- 2,4- diyne- 1,6- diylbis(oxy))bis(2,3- dihydro- 1H- indene- 2,1- diyl))bis(1- (2- cyclohexyl- 2- (2- (methylamino)propanamido)acetyl)pyrrolidine- 2- carboxamide)IBA 01/2021
1	galidesivirIBA 10/2020
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2020
1	IgG Receptors (Fc gamma RI)IBA 01/2020
1	Respiratory Syncytial Virus VaccinesIBA 11/2019
1	Opiate AlkaloidsIBA 01/2019
1	Viral ProteinsIBA 01/2018
1	Urokinase-Type Plasminogen Activator (Urokinase)FDA Link 01/2018
1	favipiravirIBA 01/2017
1	sofosbuvir drug combination ledipasvirIBA 10/2016
1	asunaprevirIBA 10/2016
1	SimeprevirIBA 10/2016
1	danoprevirIBA 01/2016
1	Silybin (Lagosa)IBA 01/2015
1	ProteomeIBA 01/2015
1	HLA-B57 antigenIBA 11/2014
1	A-Form DNA (A-DNA)IBA 07/2014
1	Nucleocapsid ProteinsIBA 07/2014
1	Interferon-betaIBA 04/2014
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2014
1	PSI 352938IBA 01/2014

Therapy/Procedure

52	Therapeutics 04/2024 - 07/2002
9	Highly Active Antiretroviral Therapy (HAART) 01/2021 - 09/2002
6	Art Therapy 10/2023 - 04/2008
5	Drug Therapy (Chemotherapy) 09/2013 - 04/2004
4	Liver Transplantation 02/2006 - 11/2002
3	Aftercare (After-Treatment) 02/2013 - 09/2002
2	Duration of Therapy 08/2015 - 04/2014
1	Intravenous Injections 10/2021